文献速递腹部MR

定量MRCP(MRCP+)用于原发性硬化性胆管炎风险分层:与形态学MRCP、MR弹性成像及生化风险评分的比较

Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores.
PubMed 文献 · Eur Radiol · 2021-07-06

本研究回顾性纳入65例原发性硬化性胆管炎(PSC)患者,评估MRCP+定量参数与生化评分及MR弹性成像(MRE)的关联。MRCP+与生化评分及MRE显著相关,其与生化评分的关联性与ANALI评分相当,联合MRE和ANALI可提高风险分层性能。

要点

  • MRCP+定量参数与PSC生化风险评分及MRE显著相关,有潜力用于风险分层。
  • MRE在风险分层上优于MRCP+,但MRCP+联合MRE和ANALI可改善整体性能。
  • 节段性狭窄总数与Mayo风险评分关联最强,狭窄最小直径与Amsterdam Oxford预后指数关联最强。

核心结论

  • MRCP+与生化评分及MRE显著相关,其与生化评分的关联性与ANALI评分大致相当。
  • MRCP+联合ANALI2和MRE可增强与Mayo风险评分的关联。

研究设计与样本

  • 回顾性研究,纳入2014年1月至2015年12月间65例PSC患者,获取MRI图像、MRE肝硬度测量和生化检测。
  • 使用MRCP+后处理MRCP图像获得胆管和胆道树的定量测量,采用线性回归分析关联性,并用自举法验证。

诊断标准与关键数值

  • 节段性狭窄总数与Mayo风险评分关联最强(R²=0.14)。
  • 狭窄最小直径与Amsterdam Oxford预后指数关联最强(R²=0.12)。
  • 宽度0-3 mm的胆管节点百分比与PSC风险估计工具关联最强(R²=0.09)。
  • 存在中位数>9 mm的胆管与MRE关联最强(R²=0.21)。
  • MRCP+与Mayo风险评分的关联强度与ANALI2相似(R²=0.23 vs 0.24),弱于MRE(R²=0.38)。

临床应用与阅片要点

  • MRCP+定量参数可用于PSC风险分层,但单独使用不如MRE。
  • 联合MRCP+、MRE和ANALI评分可提高风险分层性能。

局限性

  • 回顾性研究,样本量较小(65例),单中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To study the association of MRCP+ parameters with biochemical scoring systems and MR elastography (MRE) in primary sclerosing cholangitis (PSC). To evaluate the incremental value of combining MRCP+ with morphological scores in associating with biochemical scores.

METHODS AND MATERIALS: MRI images, liver stiffness measurements by MRE, and biochemical testing of 65 patients with PSC that were retrospectively enrolled between January 2014 and December 2015 were obtained. MRCP+ was used to post-process MRCP images to obtain quantitative measurements of the bile ducts and biliary tree. Linear regression analysis was used to test the associations. Bootstrapping was used as a validation method.

RESULTS: The total number of segmental strictures had the strongest association with Mayo Risk Score (R2 = 0.14), minimum stricture diameter had the highest association with Amsterdam Oxford Prognostic Index (R2 = 0.12), and the percentage of duct nodes with width 0-3 mm had the strongest association with PSC Risk Estimate Tool (R2 = 0.09). The presence of Ducts with medians > 9 mm had the highest association with MRE (R2= 0.21). The strength of association of MRCP+ to Mayo Risk Score was similar to ANALI2 and weaker than MRE (R2 = 0.23, 0.24, 0.38 respectively). MRCP+ enhanced the association of ANALI 2 and MRE with the Mayo Risk Score.

CONCLUSIONS: MRCP+ demonstrated a significant association with biochemical scores and MRE. The association of MRCP+ with the biochemical scores was generally comparable to ANALI scores. MRCP+ enhanced the association of ANALI2 and MRE with the Mayo Risk Score.

KEY POINTS: • MRCP+ has the potential to act as a risk stratfier in PSC. • MRE outperformed MRCP+ for risk stratifcation. • Combination of MRCP+ with MRE and ANALI scores improved overall performace as risk stratifiers.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Ismail MF, Hirschfield GM, Hansen B, et al. Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores. Eur Radiol. 2021. PMID: 34231037. doi:10.1007/s00330-021-08142-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。